





RealRate

PHARMACEUTICAL 2018

Monopar Therapeutics Rank 245 of 342





PHARMACEUTICAL 2018

Monopar Therapeutics Rank 245 of 342



The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Monopar Therapeutics is the variable Other Expenses, reducing the Economic Capital Ratio by 257% points.

The company's Economic Capital Ratio, given in the ranking table, is -0.19%, being 46% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	9,131
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	312
Liabilities, Non-Current	0
Other Assets	800
Other Compr. Net Income	0
Other Expenses	14,502
Other Liabilities	0
Other Net Income	48
Other Revenues	0
Property and Equipment	0
Research and Development	935
Selling, General and Administrative Expense	1,166

Output Variable	Value in 1000 USD
Assets	9,931
Liabilities	312
Expenses	16,603
Revenues	0
Stockholders Equity	9,619
Net Income	-16,555
Comprehensive Net Income	-16,555
Economic Capital Ratio	-0.19%